Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Sep 2021
Withdrawals from pharmaceutical benefits on 1 October 2021
8 September 2021 - Suboxone is among the medicines that will be withdrawn from the drug benefits at the companies' ...
Posted by Michael Wonder on 08 Sep 2021
Nivolumab scores a rare 'no' from NICE
8 September 2021 - Nivolumab scores only its second final rejection to date from NICE. ...
Posted by Michael Wonder on 08 Sep 2021
Ultragenyx Canada announces Health Canada approval of a second indication for Crysvita (burosumab injection) for the treatment of tumour induced osteomalacia in adults
7 September 2021 - Ultragenyx Pharmaceutical today announced that Crysvita (burosumab Injection) has been approved by Health Canada for the treatment ...
Posted by Michael Wonder on 08 Sep 2021
Intelivation Technologies received FDA approval for the Advantage-C PEEK cervical interbody fusion device
8 September 2021 - Intelivation Technologies announced today that they have achieved FDA 510(k) Clearance of the Advantage-C PEEK cervical ...
Posted by Michael Wonder on 08 Sep 2021
Phathom Pharmaceuticals submits two NDAs to U.S. FDA for vonoprazan-based treatment regimens for the treatment of H. pylori infection
8 September 2021 - Phathom Pharmaceuticals announced today that it has submitted two new drug applications to the U.S. FDA for ...
Posted by Michael Wonder on 08 Sep 2021
FDA grants Madorra breakthrough device designation status for treatment of moderate to severe vulvovaginal atrophy
8 September 2021 - Clinical trials of Madorra therapy system show promising results for treatment of vulvovaginal atrophy. ...
Posted by Michael Wonder on 08 Sep 2021
HiberCell receives fast track designation from FDA for first in human studies of PERK inhibitor (PERKi) HC-5404-FU
8 September 2021 - C-5404-FU PERKi program is currently in a Phase 1a clinical trial for the treatment of solid ...
Posted by Michael Wonder on 08 Sep 2021
Congress is ready to dig into drug prices
7 September 2021 - After months of drama and procedural votes, Congress is about to dive into the legislative process on ...
Posted by Michael Wonder on 08 Sep 2021
NICE draft guidance recommends apalutamide for treating prostate cancer
8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...
Posted by Michael Wonder on 07 Sep 2021
TGA approves new cancer medicine
7 September 2021 - Luspatercept (Reblozyl) is used to treat patients with certain transfusion-dependent anaemias. ...
Posted by Michael Wonder on 07 Sep 2021
Singapore's health care system: key features, challenges, and shifts
2 September 2021 - Since Singapore became an independent nation in 1965, the development of its health care system has been ...
Posted by Michael Wonder on 07 Sep 2021
U.S. FDA accepts for priority review supplemental new drug application for Oxbryta (voxelotor) for the treatment of sickle cell disease in children ages 4 to 11
7 September 2021 - New drug application for Oxbryta dispersible tablets also accepted for priority review. ...
Posted by Michael Wonder on 07 Sep 2021
Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer
7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...
Posted by Michael Wonder on 07 Sep 2021
To lower drug costs, define ‘cost’ to mean net cost after rebates
7 September 2021 - In what could be a turning point in the prescription drug debate, President Biden has made ...
Posted by Michael Wonder on 07 Sep 2021
Landmark new medicines agreements to bring significant benefits for Australian patients
7 September 2021 - Australians will have more affordable, improved and guaranteed access to medicines under landmark long-term strategic agreements between ...